U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests Guidance for Industry April 2008

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2007-D-0070
Issued by:
Guidance Issuing Office
Center for Biologics Evaluation and Research

This guidance provides you, an establishment1 that makes donor eligibility determinations for certain human cells, tissues, and cellular and tissue-based products (HCT/Ps), with recommendations concerning the donor eligibility and additional requirements under Title 21 Code of Federal Regulations, Part 1271, Subpart C (21 CFR Part 1271, Subpart C). This guidance updates and replaces the January 2007 guidance of the same title to clarify that for the purposes of this guidance the term “certain HCT/Ps” also includes certain donor lymphocytes for infusion (DLIs), namely those lymphocytes for infusion collected from the same donor as hematopoietic progenitor/stem cells (HPCs); • provide updated recommendations regarding donor testing2 using pooled specimens of HPCs and DLIs (as specified above) due to the approval of Biologics License Application (BLA) supplements from two nucleic acid test manufacturers (see footnotes 5 through 7); and • specify that this guidance applies to certain HCT/Ps recovered from donors beginning on or after May 25, 2005 through February 23, 2007.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2007-D-0070.

Questions?

Contact Point
Office of Communication, Outreach and Development (OCOD)
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3128
Silver Spring, MD 20993-0002
ocod@fda.hhs.gov
(800) 835-4709
(240) 402-8010
Back to Top